

December 3-5 2024 | Boston, MA  
www.personalized-cancer-vaccines.com

REGISTER BY  
MONDAY,  
DECEMBER 2 &  
SAVE UP TO \$100


WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



# Personalized Cancer Vaccine Summit

Achieving Affordable Individualized Vaccines for Cancer Patients Faster

## Advancing Personalized Cancer Vaccines with Novel Antigen Selectivity, Optimal Combination Strategies & On-Demand Manufacturing Towards Positive Clinical Readouts & First Approvals

### Expert Speakers Include:



**Lelia Delamarre**  
Director - Cancer Immunology Research & Distinguished Scientist  
Genentech



**Myriam Mendila**  
Chief Scientific Officer & Head of Research & Development  
CureVac



**David Andrews**  
Chief Medical Officer  
Imvax



**Hans Keirstead**  
Chairman & Chief Executive Officer  
AIVITA Biomedical



**Yan Asmann**  
Associate Professor of Biomedical Informatics  
Mayo Clinic



**Elisa Scarselli**  
Chief Scientific Officer  
Nouscom

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series



# Welcome to the Personalized Cancer Vaccine Summit

The cancer industry is on edge as the race toward the next efficacious personalized cancer vaccine approval continues, with 427 candidates in development including late-stage trials by **BioNTech** and **Imvax** fueling hope for the cancer revolution.

With the rise in **multiple modality approaches** in mRNA and beyond, the **Personalized Cancer Vaccine Summit** returns to Boston for the 3rd year (formerly known as the mRNA Cancer Vaccine Summit) as the most comprehensive industry-dedicated forum with leading biopharma revealing late-breaking clinical trial data, pioneering bioinformatic strategies for neoantigen identification and manufacturing innovations to advance patient-centric pipelines towards the clinic and regulatory approval.

The 3-day program will provide you with jam-packed strategic and technical insights to:

- Selecting the right neoantigen type using the latest technologies in genomic screening, artificial intelligence, and immune subtyping to improve tumor target efficacy
- Harnessing the latest modalities of choice in **mRNA, DNA, peptide, viral, dendritic cells**, and more to produce the best antigen response and maximum therapeutic benefit to cancer patients
- Optimizing the latest personalized cancer vaccine approaches with immune-checkpoint inhibitor combinations to combat multiple tumor specific pathways and minimize off-target effects
- Overcoming targeted delivery bottlenecks to ensure your personalized approach reaches the tumor-target of interest at the right time, every time
- Unlocking manufacturing strategies in sequencing, synthesis and supply to ensure small-scale and batch-to-batch consistency for on-demand production

Curated with industry insights from CureVac, Nouscom, Syncromune, Geneos Therapeutics and more, this event brings together 80+ chief leaders and experts in oncology, immunology, clinical development, and CMC, you can join this community to learn, share, and forge partnerships to validate and leverage the best personalized cancer vaccines approaches from biopsy to patient, cheaper and faster.

## What our speakers have to say:

“Since this is completely focused on personalized cancer vaccines, it is of great value for everyone working in the cancer vaccine space. I do believe that this conference will serve as a platform to understand the needs of personalized cancer treatment and the challenges of every pharma or biotech company in manufacturing a PCV”

**Prasun Chakraborty**, Founder & Chief Executive Officer, **Genevation**

“The **Personalized Cancer Vaccine Summit** is a great opportunity to exchange information with the community in an informal environment”

**Heinz Lubenau**, Chief Executive Officer, **NEC Bio Therapeutics**

## 5 KEY BENEFITS OF ATTENDING:



**Uncover** novel individualized platforms leveraging mRNA, DNA, peptide, viral vector, dendritic cell-based cancer vaccines to effectively target tumor-specific neoantigens with insights from **BioNTech**, **Université de Montréal** & **Nouscom**



**Transform** your personalized vaccine manufacturing strategy with improved sequencing, platform design and small-scale development with insights from **Mayo Clinic**, **Genevation** & **BreakBio**



**Turbocharge** your computational methods with machine learning, tumor analysis and bioinformatics to identify the most effective neoantigens with insights from **ROME Therapeutics**, **University of Waterloo** & **Achilles Therapeutics**



**Tackle** multiple tumor-specific pathways with a two-pronged combination strategy to induce a strong immune response with insights from **Nec Bio Therapeutics** & **Syncromune**



**Harness** the latest clinical trial learnings to avoid the pitfalls and accelerate your personalized candidates towards market approval with better efficacy and safety with insights from **AIVITA Biomedical**, **Imax** & **Geneos Therapeutics**

# Uncovering the Personalized Cancer Vaccine Landscape

Personalized Cancer Vaccine Summit

December 3-5, 2024 | Boston, MA

WELCOME

Over 3 days jam-packed with data driven content, explore the cutting-edge research from key companies across all stages of the personalized cancer vaccine timeline, from tumor antigen and dendritic cell analysis, to employing individualized mRNA, DNA, peptide, viral and beyond based vaccines to eradicate cancer

## What's on in 2024?



**3**  
Days of  
In-Depth  
Content



**6+**  
Hours of  
Interactive  
Networking




**15+**  
Deep  
Dive Case  
Studies



**23+**  
Expert  
Speakers

EXPERT SPEAKERS



AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

3

+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series



# Your Expert Speakers

Personalized Cancer  
Vaccine Summit

December 3-5, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**Amy Walker**  
Chief Operating Officer  
**4basebio**



**Zhinan Xia**  
Chief Scientific Officer  
**Abimmune**



**Hans Keirstead**  
Chairman & Chief  
Executive Officer  
**AIVITA Biomedical**



**Alastair Hay**  
Vice President Peptides  
**Almac**



**Gloria Castro**  
Research Analyst  
**Beacon**



**Ruben Rizzi**  
Senior Vice President  
Global Regulatory Affairs  
**BioNTech**



**David Berd**  
Chief Medical Officer  
**Biovaxys**



**Roy De Souza**  
Co-Founder & Chief  
Executive Officer  
**BreakBio**



**Myriam Mendila**  
Chief Scientific Officer  
& Head of Research &  
Development  
**CureVac**



**Lelia Delamarre**  
Director - Cancer  
Immunology Research &  
Distinguished Scientist  
**Genentech**



**Jian Yan**  
Vice President of Research  
& Discovery  
**Genes Therapeutics**



**Prasun Chakraborty**  
Founder & Chief Executive  
Officer  
**Genevation**



**David Andrews**  
Chief Medical Officer  
**Imvax**



**Sean Hemingway**  
Chief Operating Officer  
**Imvax**



**Keith Knutson**  
Professor of Immunology  
**Mayo Clinic**



**Yan Asmann**  
Associate Professor of  
Biomedical Informatics  
**Mayo Clinic**



**Heinz Lebenau**  
Chief Executive Officer  
**NEC Bio Therapeutics**



**Elisa Scarselli**  
Chief Scientific Officer  
**Nouscom**




**Sam Deutsch**  
Chief Scientific Officer  
**Nutcracker Therapeutics**




**Agnete Fredriksen**  
Chief Scientific Officer  
**Nykode Therapeutics**



**Eric Halioua**  
President & Chief  
Executive Officer  
**PDC\*Line Pharma**



**Massimo Fantini**  
Director of Research &  
Development  
**Precision Biologics**



**Wilson McKerrow**  
Principal Data Scientist  
**ROME Therapeutics**




**Charles Link**  
Executive Chairman  
**Syncromune**



**Moutih Rafei**  
Professor  
**Université de Montréal**



**Ming Li**  
Professor  
**University of Waterloo**



**William Jia**  
Co-founder & Chief  
Scientific Officer  
**Virogin Biotech**

4


+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series

**hansonwade**  
GROUP

# Manufacturing Focus Day

## Tuesday December 3, 2024

 **Personalized Cancer Vaccine Summit**  
December 3-5, 2024 | Boston, MA

A critical challenge in the personalized cancer vaccine field is the long manufacture times of the vaccine, which can take up to 4 months; this includes tumor sequencing, neoantigen target identification, and design of the mRNA, DNA, peptide, viral, or dendritic cell for the vaccine. The Pre-Conference Manufacturing Focus Day dives into key bottlenecks with innovative sequencing strategies, highlighting the importance of bioinformatics in the manufacturing pipeline, and re-imagining the scale of drug development to create the most effective therapies at an affordable price. Take this chance to participate in a day dedicated to the manufacturing challenges with the leading industry minds to streamline your neoantigen selection, harness AI strategies, and employ better design & synthesis methods.



8.00 **Coffee & Check In**



**Keith Knutson**  
Professor of Immunology  
Mayo Clinic

8.50 **Chair's Opening Remarks**

### Developing Computational Methods for Design & Neoantigen Discovery to Develop More Targeted Personalized Cancer Vaccines



**Prasun Chakraborty**  
Founder & Chief Executive Officer  
Genevation  
**Virtual**

9.00 **Conquering Design Bottlenecks by Computer-Aided Design to Improve Manufacturing Time**

- Exploring novel algorithms used in design and score mRNA structures for synthesis viability
- Diving into best design practice of personalized vaccines to achieve a T cell response
- Enhancing personalized cancer vaccine injectables and mitigating complexities by separating into fragments for more effective vaccines



**Yan Asmann**  
Associate Professor of Biomedical Informatics  
Mayo Clinic

9.30 **Exploring Tumor Sequencing, Antigen Prediction & Validation for Personalized Cancer Vaccines to Develop a Fast & Effective Workflow**

- Delving into the tumor microenvironment, novel mutational source of neoantigens, and non-canonical antigens in patients to determine the un-utilized antigens for more effective individualized therapies
- Streamlining the sequencing, prediction, and validation of tumor samples for personalized cancer vaccines by a bioinformatics workflow combining public and in-house developed algorithms
- Verifying the antigens used in individualized therapies in patients' post-vaccination blood to determine the accuracy of the workflow



10.00 **Morning Networking Break**

### Overcoming the Manufacturing Scale-Out Challenge of Personalized Cancer Vaccines to Deliver Therapies to Patients Faster



**Heinz Lubenau**  
Chief Executive Officer  
NEC Bio Therapeutics



11.00 **Roundtable Discussion: Redefining the Scale of Personalized Cancer Vaccine Manufacture as Fast & Cost-Effective Treatments**

- How to reimagine the large-scale drug development pipeline to small-scale for high-quality personalized cancer vaccines
- How to evaluate turnaround time required to create the most effective personalized cancer vaccines
- How can the cost of personalized cancer vaccines be reduced by efficient sequencing and better bioinformatics?



12.00 **Networking Lunch Break**

5

+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com  World RNA Series

**hansonwade**  
GROUP

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

# Manufacturing Focus Day

## Tuesday December 3, 2024

### Spotlighting Sequencing & Synthesis Strategies to Manufacture High Quality Personalized Cancer Vaccines on a Rapid Timescale to Obtain a Strong Immune Response



**Keith Knutson**  
Professor of Immunology  
Mayo Clinic

#### 1.00 Diving into Novel Small-Scale Manufacture of Dendritic Cells & Peptide-Based Personalized Cancer Vaccines for Efficient Production

- Maintaining quality control of peptide-based cancer vaccines on a small scale to ensure the best possible therapy
- Efficiently packing dendritic cells with multiple antigens for high patient immune response
- Uncovering innovations in peptide synthesis for individualized vaccines to shorten manufacturing time



**Roy de Souza**  
Chief Executive Officer & Co-Founder  
BreakBio Corp

#### 1.30 Employing Mass Spectrometry per Patient Combined with Machine Learning to Find the Best Targets

- Using mass spectrometry to find presented antigens per patient for a targeted, personalized vaccine
- Creating software with AI/machine learning to find cancer vaccine targets based on DNA mutations, RNA expression, and mass spectrometry per patient
- Searching for the best targets in low tumor mutational burden cancers for most effective personalized cancer vaccines



#### 2.00 Afternoon Networking Break

### Assessing the Cost, Speed, & Viability of Personalized Cancer Vaccines to Develop Targeted Therapies for More Patients

#### 3.00 Panel Discussion: Personalized vs Off-the-shelf Cancer Vaccines: Evaluating the Advantages & Disadvantages for Better Clinical Efficacy

- Debating the feasibility of individualized cancer vaccines vs targeting shared neoantigens
- Dissecting the economic viability and availability of personalized cancer vaccines for patients
- Considering the future opportunities for cancer vaccines in personalized & off-the-shelf for positive patient response



**Eric Halioua**  
President & Chief Executive Officer  
PDC\*line Pharma



**Myriam Mendila**  
Chief Scientific Officer & Head of Research & Development  
CureVac



**Zhinan Xia**  
Chief Scientific Officer  
Abimmune



**Elisa Scarselli**  
Chief Scientific Officer  
Nouscom



**Sean Hemingway**  
Chief Operating Officer  
Imvax

#### 4.00 Goldspire™: Developing a Fast Turnaround Individualized Cancer Vaccine-like Immunotherapy to Reduce Manufacturing Time & Treat Patients Faster

- Creating an individualized treatment by whole tumor to overcome heterogeneity with the most comprehensive antigens
- Reducing the personalized cancer vaccine timeline by central manufacturing and optimized logistics
- Ensuring cGMP cancer vaccine process consistency and quality by using a central manufacture site for alignment with the FDA



**Keith Knutson**  
Professor of Immunology  
Mayo Clinic

#### 4.30 Chairs Closing Remarks

#### 4.45 End of Pre-Conference Focus Day

# Conference Day One

## Wednesday December 4, 2024



Personalized Cancer  
Vaccine Summit

December 3-5, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



7.20 Morning Coffee & Check In



**Zhinan Xia**  
Chief Scientific Officer  
Abimmune

8.20 Chair's Opening Remarks

### Spotlighting Breakthrough Clinical Success for Personalized Cancer Vaccines Toward the Next Best Approval

8.30 Developing a Patient Specific Dendritic Cell Immunotherapy that Shows Effective Patient Response



**Hans Keirstead**  
Chief Executive Officer  
AIVITA Biomedical

- Developing a personal, precision medicine that minimizes adverse events and maximizes efficacy
- Employing a pan-antigenic approach to protect against mutation-associated loss of function for more powerful therapeutics vaccines
- Diving into promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival of patients

9.00 Goldspire™: A Biologic-Device Combination Immunotherapy that Induces Preclinical Anti-Tumor Responses Against Multiple Solid Tumors Shows Clinical Activity in Glioblastoma



**David Andrews**  
Chief Medical Officer  
Imvax

- Utilizing a biodiffusion chamber releasing tumor antigens and an IGF1R antisense for effective treatment of glioblastoma
- Realizing the platform configuration to maximize immunogenic cell death
- Exploring long-term survival and immunity of glioblastoma patients receiving individualized immunotherapy

9.30 Personalized Therapeutics Cancer Vaccines for Treating Advanced Cancer - Efficacy in Liver Cancer



**Jian Yan**  
Vice President of  
Research & Discovery  
Geneos Therapeutics

- Utilizing DNA-based cancer vaccines that can encode for up to 40 neoantigens to achieve powerful T cell response
- Employing personalized cancer vaccines in an advanced cancer setting to shrink tumors
- Exploring correlative biomarker analyses to understand vaccine efficacy



10.00 Morning Break & Speed Networking

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the personalized cancer vaccine field and establish meaningful business relationships to pursue for the rest of the conference

### Exploring Computational Methods to Identify the Relevant Antigens & Neoantigens to Find the Best Targets for Personalized Cancer Vaccines

11.00 Investigating Novel Dark Antigen Targets to Produce More Effective Cancer Vaccines



**Wilson McKerrow**  
Principal Data Scientist  
ROME Therapeutics

- Deploying a computational platform to measure the expression and presentation of repetitive targets
- Exploring the repeatome to identify tumor-specific repeats and find ideal targets for cancer vaccines
- Comparing tumor expressed neoantigens in public and private data for platform and target validation

11.30 NeoPeptides™ Streamlining Manufacturing for Personalized Cancer Vaccines - Current & Future Perspectives



**Alastair Hay**  
Vice President Peptides  
Almac

- Manufacture for PCVs remains a relatively niche area with pockets of true expertise
- Innovation in manufacturing methods and regulatory requirements required to meet clinical requirements
- Assuming future clinical success; how will the supply chain deliver?

7

+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series





**Ming Li**  
Professor  
University of Waterloo

### 12.00 Developing the DeepNovo Platform to Determine the Most Immunogenic Peptides to Create an Immune Response to Personalized Cancer Vaccines

- Finding novo sequences by de novo mass spectrometry sequencing to determine better neoantigen targets
- Employing AI in proteomics to discover peptides with immunogenicity for more effective cancer vaccines
- Confirming the power of bioinformatics in neoantigen detection and validation by experimental methods for best patient response to individualized cancer vaccines



### 12.30 Networking Lunch Break

## Advancing Development of DNA-Based Cancer Vaccines for Maximum Neoantigen Expression & Immune Response



**Agnete Fredriksen**  
Chief Scientific Officer  
Nykode Therapeutics

### 1.30 Utilizing a Modality-Agnostic Platform for a Head-to-Head Comparison of mRNA & DNA-based Personalized Cancer Vaccines in Creating an Immune Response

- Comparing DNA and mRNA as modalities to encode for fusion proteins in individualized cancer vaccines to effectively induce an immune response
- Utilizing a unique bioinformatics platform to target immunogenic APCs in personalized cancer vaccines for better tumor control
- Exploring DNA-based personalized cancer vaccines that produce differentiated and more effective T-cells



**Amy Walker**  
Chief Operating Officer  
4basebio

### 2.00 Synthetic, Enzymatically Produced DNA For Use in DNA & mRNA Vaccines

- 4bbDNA™ confers safety benefits, enables dose reduction and reduced timelines of GMP-grade material over plasmid DNA for both DNA and mRNA vaccine applications use in vaccine applications
- A collaboration with Neomatrix on neoantigen DNA cancer vaccines using hpDNA™ constructs showed meaningful immune responses and reduced tumour growth as compared to pDNA in clinically relevant models – phase I clinical trial anticipated for H125
- mRNA produced from 4basebio's opDNA™ templates in combination with Hermes™ nanoparticle delivery system shows enhanced immune response and reduced tumour growth comparable to conventional LNP delivery systems in several mouse models



**Heinz Lubenau**  
Chief Executive Officer  
NEC Bio Therapeutics

### 2.30 Combining DNA Cancer Vaccines with Checkpoint Inhibitors to Induce an Immune Response in the Tumor & Have a Positive Patient Response

- Enhancing the efficacy of DNA cancer vaccines using checkpoint inhibitors as standard of care to induce a strong immune response
- Exploring self-adjuvanted therapies with personalized cancer vaccines for best patient response
- Employing a double-edged sword of checkpoint inhibitors and the high peptide capability of DNA-based cancer vaccines as effective therapies



### 3.00 Afternoon Break



# Conference Day One

## Wednesday December 4, 2024



Personalized Cancer  
Vaccine Summit

December 3-5, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

### Discovering Other Modalities in Cancer Vaccines for Increased Safety, Targeted Delivery, & More Effective Vaccines



**Moutih Rafei**  
Professor  
**Université de Montréal**

#### 4.00 **AccuTOX-Reprogrammed Mesenchymal Stromal Cells (ARM-X): An Alternative Cellular Vector for Cancer Immunotherapy**

- Reprogramming mesenchymal stromal cells in individualized cancer vaccines to present antigens to the immune system
- Employing a fast design and manufacture method of personalized cancer vaccines that is applicable to many indications for effective tumor control
- Unearthing the use of cancer vaccines with checkpoint inhibitors for hard-to-treat cancers



**Sam Deutsch**  
Chief Scientific Officer  
**Nutcracker Therapeutics**

#### 4.30 **Personalized Cancer Vaccines Need Personalized Manufacturing**

- Demonstrating the Nutcracker® Manufacturing Unit (NMU) - Amplifying a DNA template, transcribing it into RNA
- in vitro, and packaging into a proprietary nanoparticle – and miniaturizing them into fully enclosed microfluidics pathways on biochips
- Showcasing the advantages a microfluidics approach with the NMU for the nanoscale volumes that RNA is manufactured in
- Unlocking the NMU's potential to excel in creating personalized medicines and scalability for treatments intended for hundreds of thousands of patients



**Elisa Scarselli**  
Chief Scientific Officer  
**Nouscom**

#### 5.00 **Uncovering the Best Strategies to Employ Neoantigens Vaccines for the Most Effective Therapies**

- Utilizing murine models to identify the patient profiles that are most effective for personalized cancer vaccines
- Exploring the timing and dosage schedule of personalized cancer vaccines to improve translation to the clinic
- Determining the optimal combination therapy strategy with personalized vaccines for better cancer treatment



**Eric Halioua**  
President & Chief Executive Officer  
**PDC\*line Pharma**

#### 5.30 **New Class of Antigen-Specific Cancer Active Immunotherapies Based on a Potent Presenting Cell Line (PDC\*line)**

- PDC\*line is a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of plasmacytoid dendritic cells
- Presentation of the first results of the ongoing phase I/II clinical trial for NSCLC patients
- Initiation of a phase Ib clinical trial with a personalized neoantigen based vaccine in CRC patients



**Zhinan Xia**  
Chief Scientific Officer  
**Abimmune**

#### 6.00 **Chair's Closing Remarks & End of Conference Day One**

■ ■ The Personalized Cancer Vaccine Summit efficiently brings together key opinion leaders, practitioners, and cGMP manufacturers to focus on the variety of cancer vaccine approaches and streamline delivery to maximize clinical activity ■ ■

**Mark Exley, Chief Scientific Officer, Imvax**



+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series



# Conference Day Two

## Thursday December 5, 2024

Personalized Cancer  
Vaccine Summit  
December 3-5, 2024 | Boston, MA

WELCOME



7.50 Morning Coffee & Networking



**Myriam Mendila**  
Chief Scientific Officer  
& Head of Research &  
Development  
**CureVac**

8.50 Chair's Opening Remarks

### Supercharging the Development of Personalized Cancer Vaccines by Overcoming Regulatory Challenges in the Clinic to Achieve Market Approval



**Lelia Delamarre**  
Director - Cancer  
Immunology Research  
& Distinguished  
Scientist  
**Genentech**

9.00 **Challenges & Promises of Personalized Cancer Vaccines: Learnings From Autogene Cevumeran**

- Preclinical studies: vaccine immunogenicity and anti-tumor response
- Showcasing phase 1 clinical data
- Determining the vaccine mechanism of action



**Ruben Rizzi**  
Senior Vice President  
Global Regulatory  
Affairs  
**BioNTech**  
**Virtual**

9.30 **Developing a Fully Individualized mRNA Cancer Immunotherapy: Regulatory Innovation & Challenges**

- Lessons learned from the development of fully individualized mRNA immunotherapy across multiple tumor types
- Key questions to identify the most appropriate development strategy
- Navigating an evolving regulatory landscape and identifying the areas of uncertainty

10.00 **Panel Discussion: Examining the Pathway of Personalized Cancer Vaccines From a Range of Modalities Through the Clinic to Get Effective Therapies to Patients Faster**

- Uncovering how successful trials are in selecting patients and achieving clinical efficacy
- Understanding the importance of durability and half-life of vaccines in patients for a swift journey through the clinic
- Navigating the regulatory frameworks for personalized medicine to ensure success post-approval



**Hans Keirstead**  
Chief Executive Officer  
**AIVITA Biomedical**



**Jian Yan**  
Vice President of  
Research & Discovery  
**Genes Therapeutics**



**Agnete Fredriksen**  
Chief Scientific Officer  
**Nykode Therapeutics**



10.45 Morning Break & Networking

### Unlocking Personalized Vaccine Development for Different Indications of Cancer to Induce an Immune Response to Shrink the Tumor



**William Jia**  
Co-founder & Chief  
Scientific Officer  
**Virogin Biotech**

11.30 **Developing Personalized Cancer Vaccines for 'Cold' Tumors to Create a Successful Therapy**

- Turning cold tumors to hot by attracting immune cell infiltration and cytokine release with intratumorally infected oncolytic viruses
- Inducing tumor cell lysis to release the entire neoantigens of the tumor as personalized intratumor vaccination to broaden tumor specific T-cell repertoire.
- Employing a prime-boost strategy with tumor vaccine as a prime and intra-tumoral infection with oncolytic virus as a boost to enhance anti-tumor immunity



**Keith Knutson**  
Professor of  
Immunology  
**Mayo Clinic**

12.00 **Overcoming the Challenges in Targeting Low Tumor Mutational Burden Cancers for Improved Therapies**

- Utilizing neoantigen personalized vaccines in lung, breast, and colorectal cancers to evoke an immune response
- Examining the clinical efficacy of cancer indications with low tumor burden to highlight the therapeutic impact of personalized cancer vaccines
- Overcoming difficulties in treating low tumor mutational burdens in cancers using dendritic cell-based personalized cancer vaccines that show clinical efficacy

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

10

+1 617 455 4188 @ info@hansonwade.com

www.personalized-cancer-vaccines.com World RNA Series



# Conference Day Two

## Thursday December 5, 2024

Personalized Cancer  
Vaccine Summit  
December 3-5, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



12.30 Networking Lunch Break

### Uncovering Best Strategies With Clinical Trial Design & Regulations to Achieve Efficacy



**Gloria Castro**  
Research Analyst  
Beacon

1.30 **Personalized Cancer Vaccine: Drugs & Trials Landscape Overview**

- Examining trends in investigated disease indications for preclinical vs clinical drugs
- Analyzing the personalized cancer vaccine therapeutic class distribution
- Trials evaluating personalized cancer vaccines: phase of development



**Massimo Fantini**  
Director of Research &  
Development  
Precision Biologics



2.00 **Roundtable Discussion: Individualized Cancer Vaccines: Development Strategies for Neoantigen Selection, Clinical Development & Regulatory Approval**

- How to determine the best clinical setting for individualized cancer therapies for the easiest path through the clinic
- What is the best strategy for combination therapies to make the vaccine more effective and overcome the cancer in the long term? Why should we go down the combination route?
- What is the ideal endpoint for clinical trials when approaching regulatory agencies? Should we aim to prolong survival or develop individualized immunotherapies to have lower toxicity?



2.45 Afternoon Break & Networking

### Probing into Novel Delivery & Combination Therapies for Vaccines to Effectively Target Cancer



**Charles Link**  
Executive Chairman  
Syncromune

3.30 **Utilizing Personalized SYNC-T Therapy in situ Vaccination & Intramural Infusion to Induce Systemic Responses in Patients with Metastatic Castrate-Resistant Prostate Cancer**

- Targeting metastatic castrate-resistant prostate cancer (mCRPC) to improve response to immunotherapy
- Showcasing the personalized in-situ tumor vaccine from device-induced partial cryolysis of a targeted solid tumor
- Combining in-situ vaccine with immediate intratumoral infusion of a multi-target proprietary drug candidate SV-102 to induce a systemic immune response



**David Berd**  
Chief Medical Officer  
Biovaxys

4.00 **A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies**

- The DPX™ platform is a novel delivery system for packaging multiple proteins, peptides, cancer neoantigens, viruses and viral-like particles, and polynucleotides
- The DPX™ package is highly versatile and can accommodate multiple peptides plus immunostimulants, such as macrophage activators
- DPX™ is highly stable, and remains localized at the injection site, thereby avoiding potential systemic toxicities



**Myriam Mendila**  
Chief Scientific Officer  
& Head of Research &  
Development  
CureVac

4.30 **Chair's Closing Remarks**

4.45 **End of the Personalized Cancer Vaccine Summit**



## Expertise Partner

Almac has been supplying peptides to the research community and for clinical trials for 30 years. The field of personalized cancer vaccines required a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a world leading offering to meet all of those demands, which can be tailored to meet specific client needs. Think Almac for peptide excellence.

[www.almacgroup.com/api-chemical-development/peptide-protein-technology](http://www.almacgroup.com/api-chemical-development/peptide-protein-technology)



## Expertise Partner

4basebio enables next generation cell and gene therapies and vaccines with its technologies and solutions. We design, manufacture and supply application-specific synthetic DNA or mRNA, as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmid DNA. Our proprietary non-viral delivery system, Hermes™, confers enhanced stability over conventional LNP platforms, and is suitable for a range of nucleic acid and biological payloads, including synthetic DNA

[www.4basebio.com](http://www.4basebio.com)



## Expertise Partner

Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics' technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches

[www.nutcrackerx.com](http://www.nutcrackerx.com)



## Event Partner

Epitopea is a cancer immunotherapeutic company developing accessible off-the-shelf RNA-based immunotherapies. The company has identified novel aberrantly expressed tumor-specific antigens (aeTSA's) that are hidden in non-canonical DNA, known as Cryptigen™ TSAs, using its proprietary CryptoMap™ platform. These hidden Cryptigen™ TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal.

[www.epitopea.com](http://www.epitopea.com)



## Event Partner

We are a clinical trial and pipeline database solution designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving drug development landscape. For more information or to request a demo, visit our website.

[www.beacon-intelligence.com](http://www.beacon-intelligence.com)



## Event Partner

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.

[www.foundationmedicine.com](http://www.foundationmedicine.com)



## Event Partner

LineaRx™, an Applied DNA Sciences, Inc. company, delivers enzymatically-produced Linea™ DNA as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity and scalability to support the next generation of nucleic acid-based therapies. Produced using a proprietary, large-scale polymerase chain reaction ("PCR") based manufacturing platform, Linea DNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.

[www.linearxdna.com](http://www.linearxdna.com)

■ ■ This is an opportunity to share and discuss knowledge and new technologies. It is also a great opportunity to network with KOLs and major pharma players in the immuno-oncology space ■ ■

**Mouthih Rafei, Professor, Université de Montréal**

■ ■ By bringing together academic and industry experts in the field, the Personalized Cancer Vaccine Summit has great potential to advance our understanding of how to use personalized vaccines for cancer treatment and prevention ■ ■

**Keith Knutson, Professor of Immunology, Mayo Clinic**

# Partner With Us

## Your Global Platform to Foster New & Existing Relationships within the Rapidly Expanding Personalized Cancer Vaccine Field

The **Personalized Cancer Vaccine Summit** is your premium opportunity to showcase your expertise, raise brand awareness, and benchmark yourself as a key thought-leader and solutions provider within the personalized cancer vaccine community.

Join us to demonstrate how your business can empower key drug developers and leading experts in overcoming the hurdles of sequencing, neoantigen identification, delivery, clinical translation, and cancer vaccine manufacturing to accelerate their R&D platforms to deliver affordable individualized vaccines to cancer patients faster.



### Spearhead the Market Changes

Learn more about where the personalized cancer vaccine field is headed with the successes through the clinic, what it needs from you, and how you can best support your clients to achieve market approval



### Bond with Industry Trailblazers

Meet leaders from the cutting-edge pharma and biotechs in the personalized cancer vaccine field including the likes of **Nouscom, Imvax, PDC\*line Pharma** and more, developing meaningful connections, collaborations whilst forging potential partnerships



### Distinguish Yourself from Your Competitors

This is your golden opportunity to show the individualized cancer vaccine field how your unique services in rapid sequencing, biomarker discovery, and clinical trial management can help streamline their discovery to development pipelines and win amongst the competition



### Showcase Your Scientific Services


Jump at this chance to demonstrate your expertise to the personalized cancer vaccine field with a dedicated talk or exhibition booth to showcase your knowledge to ease drug developers to the clinic and beyond



### Build Lasting Connections

Take advantage of the different branding opportunities to increase your exposure and create a lasting impression on influential personalized cancer vaccine biopharma companies, ensuring they think of you as the go-to solution provider

## SENIORITY OF ATTENDEES\*



\*Statistics Taken from previously branded mRNA Cancer Vaccine Summit, 2023\*

“ This is the go-to conference in personalized medicine and personalized cancer vaccines. Our new era of personalized drugs, designed and manufactured per patient, has started to show exciting clinical results ”

**Roy De Souza, Co-Founder & Chief Executive Officer, BreakBio**

## GET INVOLVED



**Maia Sethi**


Business Development Manager


Tel: +1 617 455 4188


Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

# Ready to Register?

## 3 Easy Ways to Book

 [www.personalized-cancer-vaccines.com/take-part/register/](http://www.personalized-cancer-vaccines.com/take-part/register/)

 Tel: +1 617 455 4188

 Email: [info@hansonwade.com](mailto:info@hansonwade.com)



**ACCELERATE** your pipeline with the innovative and novel methods being used in sequencing, neoantigen identification, and design to improve the manufacturing time of personalized cancer vaccines



**PERSONALIZE** your networking approach with biopharma leaders to grow your network, create bonds, and possible collaborations to share your complementary technologies



**UNCOVER** the cross-learnings between mRNA, DNA, and peptide-based platforms in personalized cancer vaccines and how it can help you more effectively target the tumor

Drug Developer Pricing*	Register & Pay By Monday, December 2	On the Door Price
Conference + Manufacturing Day	\$4,097 (Save \$100)	\$4,197
Conference Only	\$2,899 (Save \$100)	\$2,999
Academic & Not-for-Profit Pricing**	Register & Pay By Monday, December 2	On the Door Price
Conference + Manufacturing Day	\$3,497 (Save \$100)	\$3,597
Conference Only	\$2,499 (Save \$100)	\$2,599
Service & Solution Provider Pricing	Register & Pay By Monday, December 2	On the Door Price
Conference + Manufacturing Day	\$4,947 (Save \$100)	\$5,097
Conference Only	\$3,599 (Save \$100)	\$3,699


\*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

\*\*To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

## Team Discounts\*\*\*

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

\*\*\*Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.  
Contact: [register@hansonwade.com](mailto:register@hansonwade.com)



## Venue

**Hilton Boston Back Bay**  
40 Dalton Street, Boston, MA 02115

For further information or assistance, please visit:  
[www.hilton.com/en/hotels/bosbhhh-hilton-boston-back-bay/](http://www.hilton.com/en/hotels/bosbhhh-hilton-boston-back-bay/)

### TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom